Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma

Morton Coleman, Philip E. Lammers, Fabio Ciceri, Ira A. Jacobs

Research output: Contribution to journalArticlepeer-review

Abstract

Diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma (NHL), is the most-common subtype of NHL. DLBCL can be classified into at least 3 major immunologically distinct types, which contributes to considerable variation in disease prognosis and response to treatment. DLBCL potentially is curable, even when diagnosed at advanced stages. The current standard of care for most patients with untreated or relapsed/refractory DLBCL is chemoimmunotherapy containing rituximab, an anti-CD20 monoclonal antibody. With advanced understanding of the molecular mechanisms involved in the pathogenesis of DLBCL and specific signaling pathways that are activated in different subtypes, potential new therapeutic targets have been identified, some of which are at the late stages of clinical development. This review summarizes the critical role of rituximab in the current standard of care treatment for DLBCL and discusses why rituximab is likely to remain an important component of treatment options for DLBCL in the foreseeable future. In addition, current and emerging therapeutic agents, including potential benefits of rituximab biosimilars, for patients with DLBCL are discussed. The advent of rituximab biosimilars may facilitate accessibility of rituximab-based chemotherapies to patients with DLBCL and has potential cost-saving benefits for healthcare systems globally.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Keywords

  • Anti-CD20 monoclonal antibody
  • Chemoimmunotherapy
  • DLBCL
  • Non-Hodgkin lymphoma
  • R-CHOP

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.

Cite this